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Abstract
Background: Migraine is a neurovascular primary headache disorder, which causes significant socioeconomic problems
worldwide. The pathomechanism of disease is enigmatic, but activation of the trigeminovascular system (TS) appears to
be essential during the attack. Migraine research of recent years has focused on neuropeptides, such as calcitonin gene-
related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide 1–38 (PACAP1–38) as potential pathogenic
factors and possible therapeutic offensives. The goal of present study was to investigate the simultaneous expression of
CGRP and precursor of PACAP1–38 (preproPACAP) in the central region of the TS in a time-dependent manner following
TS activation in rats.
Methods: The right whisker pad of rats was injected with 50 μl Complete Freund’s Adjuvant (CFA) or saline. A mechanical
allodynia test was performed with von Frey filaments before and after treatment. Transcardial perfusion of the animals
was initiated 24, 48, 72 and 120 h after injection, followed by the dissection of the nucleus trigeminus caudalis (TNC). After
preparation, the samples were stored at − 80 °C until further use. The relative optical density of CGRP and preproPACAP
was analyzed by Western blot. One-way ANOVA and Kruskal-Wallis followed by Tukey post hoc test were used to
evaluate the data. Regression analysis was applied to explore the correlation between neuropeptides expression and
hyperalgesia.
Results: Orofacial CFA injection resulted in significant CGRP and preproPACAP release in the TNC 24, 48, 72 and 120 h
after the treatment. The level of neuropeptides reached its maximum at 72 h after CFA injection, corresponding to the
peak of facial allodynia. Negative, linear correlation was detected between the expression level of neuropeptides and
value of mechanonociceptive threshold.
Conclusion: This is the first study which suggests that the expression of CGRP and preproPACAP simultaneously
increases in the central region of activated TS and it influences the formation of mechanical hyperalgesia. Our results
contribute to a better understanding of migraine pathogenesis and thereby to the development of more effective
therapeutic approaches.
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Background
Recently, two peptides of key molecules have been
highlighted for their involvement in the pathomechanism
of primary headache disorders: calcitonin gene-related
peptide (CGRP), as an “old warrior” and pituitary adenyl-
ate cyclase-activating polypeptide 1–38 (PACAP1–38),
which is a newer, potential target for headache therapies.
These peptides are very similar in features and functions:
e.g. they are potent vasodilators, they are present in both
the peripheral and central nervous system and they can
function in the transmission of nociception and neuro-
genic inflammation. Subsequently, they have gained
ground in the therapeutic developments in migraine. In
2004, the first CGRP receptor antagonists (gepants) effect-
ively terminated migraine in humans, but nowadays
several other anti-CGRP treatments are in clinical trials or
are under development (anti-CGRP and anti-CGRP recep-
tor monoclonal antibodies) for the prevention of migraine
[1]. PACAP1–38 also has pivotal role in migraine, as indi-
cated by several preclinical [2–4] and clinical [5–9] exami-
nations, but there are fewer confirmed results targeted on
the PACAP1–38 antibody therapies [10]. The analogous
behaviour of these peptides presents the possibility that
anti-PACAP1–38 treatments could provide a therapeutic
advantage for migraineurs who do not respond the
anti-CGRP therapies.
Thus it is interesting to investigate the simultaneous re-
lease of CGRP and precursor of PACAP1–38 (preproPA-
CAP) in a migraine-related environment. In our case, the
orofacial Complete Freund’s Adjuvant (CFA) rat model
was selected to determine these alterations. CFA has been
used for animal modelling of autoimmune and inflamma-
tory illnesses for nearly 50 years and it is an accepted
model of orofacial inflammatory hyperalgesia [11–16].
The precise mode of action of CFA is not known, but it
primarily triggers an inflammatory reaction through the
activation of the cellular immune response [11]. The
CFA-induced chemical stimulation of the orofacial area
can activate the extra- and intracranial trigeminal primary
afferents, which provide the sensory innervation of the face
and oral cavity, as well as the vasculature-associated men-
ingeal nociceptive afferents. The cell bodies of these per-
ipheral fibres are located in the trigeminal ganglion (TRG),
while the central projections of these neurons terminate in
the trigeminal nucleus caudalis (TNC). Sensitisation of the
peripheral fibres and the second order nociceptive neurons
in the TNC can contribute to the phenomenon of facial
allodynia developing in primary headache disorders [17].
Perception of pain can be connected to the thalamic third
order neurons [18–22].
This commonly used peripheral inflammation model
can integrate those mechanisms which are involved in
migraine, because several primary headache diseases as-
sociated with inflammation of extracranial structures,
such as the temporomandibular joint (TMJ) or the si-
nuses, can be evoked by similar mechanisms to those
mentioned above [16, 23, 24]. Comorbidity was also ob-
served between migraine and TMJ disorders [25], there-
fore orofacial inflammation induced by CFA might be
suitable to generate hyperalgesia/allodynia on the face by
the activation/sensitization of the trigeminovascular sys-
tem (TS), namely to mimic the features of migraine [12].
In the course of our research we aimed to model
allodynia-associated activated TS using CFA in rats. We
used von Frey filaments to assess nociceptive sensitization
and measure the temporal changes in facial mechano-noci-
ceptive threshold after periods of 24, 48, 72, and 120 h fol-
lowing CFA injection. In order to estimate the release of
neuropeptides in the TNC in the assessed time periods
following CFA injection, Western blot assay was used with
specific preproPACAP and CGRP antibodies.
This the first study which evaluated the presence of pre-
proPACAP and CGRP together in the TNC and correlated
the behavioural changes following facial inflammation.
These investigations might provide better insight into the
background of trigeminal pain disorders.
Materials and methods
Animals
Thirty young adult (10–12 weeks old) male Sprague-Daw-
ley rats were used for the experiments. The animals were
bred and maintained under standard laboratory conditions
with a 12–12-h light/dark cycle at 24 ± 1 °C and approx.
50% relative humidity in the Laboratory Animal House of
the Department of Neurology. The rats had free access to
standard rat chow and water.
Ethics
All experimental procedures performed in this study com-
plied fully with the guidelines of Act 1998/XXVIII of the
Hungarian Parliament on Animal Experiments (243/1988)
and with the recommendations of the International Asso-
ciation for the Study of Pain and European Communities
Council (86/609/ECC). The studies were in harmony with
the Ethical Codex of Animal Experiments and were
approved by the Ethics Committee of the Faculty of Medi-
cine, University of Szeged, XI./1102/2018.
Drugs
Complete Freund’s Adjuvant (killed mycobacteria sus-
pended in paraffin oil; 1 mg/ml) was obtained from
Sigma-Aldrich Corporation (St. Louis, MO, USA), and
50 μl was administered per animal.
Orofacial pain sensitivity tested with von Frey filaments
In this experiment mechanical pain thresholds of the
orofacial region were determined with von Frey fila-
ments. Tests were performed before (0) and at 24, 48,
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72, 120 h after CFA/saline injection. Animals were lightly
restrained using a soft cotton glove in order to allow an
easier habituation, then a set of calibrated nylon mono-
filaments (SENSElab – AESTHESIOMETER, SOMEDIC
Sales AB, Box 194, 242 31 Hörby) was used with
increasing strengths (0.39–8.3 g) to measure facial
mechanosensitivity. Filaments were applied in ascending
order, starting from the 3.3 g filament during control
measurements and the 0.39 g filament after CFA treat-
ment. The mechanonociceptive threshold was defined as
the lowest force evoking at least two withdrawal
responses (face stroking with the forepaw or head shak-
ing) out of five stimulations [12].
Experimental protocol
In our experiment five animal groups were created: 1
control group and 4 groups with CFA treatment. The
groups and treatments are presented in Table 1.
First, the rats were anesthetized with intraperitoneal 4%
chloral hydrate solution (10ml/kg bw dose) and the
anesthesia was maintained throughout the experiment.
Next, 50 μl of CFA was injected into the right whisker pad.
Control rats were injected with an equal volume of saline.
The von Frey allodynia test was performed before and after
treatment, as described above. Transcardial perfusion of the
animals with 200ml phosphate-buffered saline (PBS) was
initiated 24, 48, 72 and 120 h after injection. The medullary
segment containing TNC (between rostral 1mm and cau-
dal 5mm from the obex) was removed. After preparation,
the samples were stored at − 80 °C until further use. The
relative optical density of CGRP and preproPACAP was
analyzed by Western blot.
Protein quantification by Western blot analysis
The samples were sonicated in ice-cold buffer containing
50mM Tris-HCl, 150mM NaCl, 0.1% Igepal. 0.1% cholic
acid, 2mg/ml leupeptin, 2mM phenylmethylsulphonyl
fluoride, 1mg/ml pepstatin, 2mM ethylenediaminetetra-
acetic acid (EDTA), and 0.1% sodium dodecyl sulfate (SDS).
After homogenization, the samples were centrifuged at
12.000 rpm for 10min at 4 °C, and supernatants were
aliquoted and stored at 20 °C until use. The protein concen-
tration was determined by the BCA Protein Assay Kit using
BSA as the standard. Prior to protein separation, each
sample was mixed with the sample buffer, and denatured
by boiling for 5min. Equal amounts of protein samples (20
mg/lane) were separated by standard SDS polyacrylamide
gel electrophoresis on 10% Tris-Glycine gel and electro-
transferred onto an AmershamHybond-ECL nitrocellulose
membrane (0.45-mm pore size). We used the Page Ruler
Prestained Protein Ladder (10–170 kDa) to define ap-
proximate molecular weights. Following blotting, the
membranes were blocked for 1 h at room temperature in
Tris-buffered saline containing Tween 20 (TBST) and 5%
nonfat dry milk powder. Subsequently, the membranes
were incubated in TBST containing 1% nonfat dry milk
and anti-PACAP antibody (against the C terminal;
ab174982, dilution: 1:500, incubation parameters: over-
night, 4 °C) or anti-CGRP antibody (Sigma-Aldrich-c8198,
dilution: 1:2000, incubation parameters: overnight, room
temperature), anti-glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) antibody (D16H11, dilution: 1:1000,
incubation parameters: overnight, room temperature).
The following day, the membranes were incubated in
TBST containing 1% nonfat dry milk powder and horse-
radish peroxidase-conjugated goat anti-rabbit secondary
antibody (sc-2030, Santa Cruz Biotechnology) for 2 h at
room temperature. The protein bands were revealed with
Syngene PXi 6 Access Touch Gel Documentation System.
Statistical analysis
The Shapiro-Wilk test was used to determine the distribu-
tion of data. Data of the Western blot analysis followed a
normal distribution, so after the One-way ANOVA test we
used the Tukey’s post hoc test to analyze the results. The
data from the von Frey allodynia test did not show a nor-
mal distribution, therefore we used the Kruskal-Wallis test
with Tukey’s post hoc test. A probability level of p < 0.05
was considered significant. Mean ± SD are represented in
the diagrams. Regression analyses were performed between
the levels of neuropeptides and the value of hyperalgesia
with SPSS 20.0 Software.
Results
Orofacial CFA treatment resulted in significant
preproPACAP increase in the TNC
A significant increase in the relative optical density of
preproPACAP was observed 24 (0.58), 48 (0.69), 72
(1.01) and 120 (0.85) hours after CFA treatment com-
pared to the control group (0.49). The highest prepro-
PACAP concentration was measured 72 h after the CFA
treatment. The difference between the 72 h and 120 h
groups was significant, therefore we did not feel it neces-
sary to include other group investigations (Figs. 1 and 2).
Table 1 Experimental groups
Group Control
(n = 6)
CFA 1.
(n = 6)
CFA 2.
(n = 6)
CFA 3.
(n = 6)
CFA 4.
(n = 6)
Orofacial treatment 50 μl saline 50 μl CFA 50 μl CFA 50 μl CFA 50 μl CFA
Perfusion and dissection 24 h after treatment 24 h after treatment 48 h after treatment 72 h after treatment 120 h after treatment
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Orofacial CFA treatment significantly elevated CGRP
relative optical density in the TNC
CGRP expression in the TNC was elevated 24 (0.99), 48
(1.26), 72 (2.36) and 120 (2.1) hours after CFA injection
compared to the control group (0.73). The highest
CGRP concentration was detected 72 h after CFA treat-
ment. The difference was significant between the 72-h
and 120-h groups, therefore we did not feel it was neces-
sary to include other group investigations (Figs. 3 and 4).
Orofacial CFA injection decreased the
mechanonociceptive threshold
The facial mechanonociceptive threshold decreased sig-
nificantly compared to the contralateral side 48, 72 and
120 h after CFA treatment. Compared to the control
measurement (7.77), the threshold was reduced signifi-
cantly 24 (6.64), 48 (4.1), 72 (2.1) and 120 (2.77) hours
after CFA treatment. Allodynia reached its maximum at
72 h, as the threshold change was lower by 120 h. We
did not find significant differences in the threshold of
the contralateral whisker pad area (Fig. 5).
Correlation between neuropeptides expression and
mechanical hyperalgesia
Reverse relationship was observed between the concen-
trations of neuropeptides and the value of the evoked
mechanical threshold (CFA treated whisker pad) de-
pending on the time. All data of the saline treated con-
trol group and the CFA treated groups were involved in
the statistical probe. Regression analyses have revealed
that negative, linear correlation is found between the ex-
pression levels of preproPACAP or CGRP and the levels
of hyperalgesia. Then data were mixed with bootstrap
analyses (1000x), which resulted in the following values:
n = 30, pCGRP < 0.001, RCGRP = -0.846; n = 30, ppreproPA-
CAP < 0.001, RpreproPACAP = − 0.792 (Fig. 6).
Discussion
Migraine research in recent years has focused on neuro-
peptides as potential pathogenic factors and possible
therapeutic alternatives. Neuropeptides such as hemokinin
A, neurotensin, substance P (SP), CGRP and PACAP1–38
can activate mast cells, leading to the secretion of
Fig. 1 Relative optical density of the preproPACAP protein in the TNC following orofacial CFA treatment. *** p < 0.001 vs. Control group, ** p < 0.01 vs.
Control group, ## p < 0.01 vs. 120 h group, Mean ± SD, n = 6
Fig. 2 Western blot of preproPACAP and GAPDH expression in the TNC
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vasoactive, proinflammatory and neuro-sensitizing media-
tors, thereby contributing to the activation of TS [26, 27].
The aim of the present study was to investigate the
simultaneous expression of CGRP and preproPACAP in
the central region of the TS in a time-dependent manner
following orofacial CFA treatment. Orofacial CFA injec-
tion evokes significant CGRP and preproPACAP
increase in the TNC 24 h after treatment. The neuropep-
tide levels reach a maximum at 72 h after CFA injection,
corresponding to the peak of facial allodynia.
Our opinion is that the CFA-induced inflammation
can evoke continuous and long-term neuropeptide re-
lease in the TNC, which is accompanied by manifest-
ation of mechanical hyperalgesia. It is assumed that the
CFA can maintain this effect until 72 h, then both the
preproPACAP and CGRP level start to decrease in the
absence of stimulus, which causes the relief of allodynia.
Our presumption is supported by a recent study, where
the repetitive electrical stimulation of dura mater in-
duced elevation in the expression level of CGRP and
PACAP in the TRG and TNC in rat depending on the
stimulation periods (1, 3 and 7 days). It suggests that the
number of stimulations can influence the release and ef-
fects of neuropeptides [28]. Our results are consistent
with a previous study, where the orofacial CFA injection
provoked increased CGRP expression in the TNC, which
elevation reached its maximum 3 days after CFA treat-
ment [12]. In another study, activated microglial cells
were detected in the ipsilateral TNC and in the cervical
dorsal horn 72 h after orofacial CFA treatment of rats
[29]. In this context, the activated microglial cells might
also be involved to the mechanism of central
sensitization and nociception [30–32]. It is proved that
an antagonist of P2X4 microglia receptor blocked the
NTG-induced c-Fos and CGRP release in the TNC, sub-
sequently the hyperalgesia [33]. Results of our functional
test showed that orofacial CFA injection can already
cause a significant increase in mechanical allodynia 24 h
after treatment. Allodynia reached its maximum on day
3, as the threshold change was lower by day 5. These
Fig. 3 Relative optical density of the CGRP protein in the TNC following orofacial CFA treatment. *** p < 0.001 vs. Control group, ** p < 0.01 vs.
Control group, # p < 0.05 vs. 120 h group, Mean ± SD, n = 6
Fig. 4 Western blot of CGRP and GAPDH expression in the TNC
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results are consistent with observations from animal in-
vestigations where the CFA induced chronic pain-like
behaviour 3 days after treatment [12, 14, 34]. Addition-
ally, it was also demonstrated that chronic stimulation of
dura mater can elicit facial cutaneous allodynia during
the migraine chronification, via CGRP and PACAP
elevation. One of the potential mechanisms, which can
mediate the effect of PACAP is that its autoreceptor
(PAC1) can influence the G-protein-coupled down-
stream effects via regulating the pre- and postsynaptic
events [28]. Nevertheless, the moderating functional al-
terations might also be explained by the desensitization
of receptors, but further investigations are needed to an-
swer this hypothesis.
Another important result of present study is that the
alterations of CGRP and preproPACAP expression show
correlation with change of mechanical threshold. Several
studies have proved to the key role of CGRP and
PACAP1–38 mediators of neurogenic inflammation and
modulators of pain inputs [2, 35, 36]. The release of
these neuropeptides in the central nervous system
facilitate nociceptive signalling and in the periphery con-
tribute to vasodilatation of meningeal vessels and neuro-
genic inflammation [37]. Based on our results probable
that the CFA-induced CGRP and PACAP1–38 increase
play crucial role in triggering central sensitization,
thereby regulation of these peptides may influence the
rate of mechanical hyperalgesia [38].
Fig. 5 Changes in mechanical theshold before (0) and 24, 48, 72, 120 h after CFA treatment. *** p < 0.001 vs. Control measurement (0 h) in CFA
treatment group, ** p < 0.01 vs. Control measurement (0 h) in CFA treatment group, ### p < 0.001 vs. contralateral side. Mean ± SD, n = 6–24
Fig. 6 Negative, linear correlation between expression levels of neuropeptides and mechanonociceptive threshold
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Role of neuropeptides in preclinical migraine models
A classical study confirmed that the concentration of CGRP
and SP were increased during electrical stimulation of TRG
(ES-TRG) of the external jugular vein of cats [39]. A former
study suggests that ES-TRG resulted in significantly ele-
vated PACAP1–38 immunoreactivity 180min after
ES-TRG of the plasma and PACAP1–38 and PACAP1–27
immunoreactivity in the TNC. Besides ES-TRG, the intra-
peritoneal administration of nitroglycerin (NTG) also
induced an increase in PACAP1–38 and PACAP1–27 ex-
pression 3 h after the treatment in the TNC [3]. A study
showed that PACAP1–38 administration can result in in-
creased CGRP expression in the TNC, which points to a
potential connection between release of CGRP and
PACAP1–38 [40]. Co-expression of CGRP and PACAP1–
38 was investigated: 23% of the neurons expressed both
CGRP and PACAP1–38 in rat TRG, and CGRP (49%) was
expressed in more neuronal somas compared to PACAP1–
38 (29%) [41]. In a preclinical model of migraine, the simul-
taneous release of CGRP and PACAP was detected: a
chronic NTG treatment caused increased concentrations of
these peptides in the plasma of rats, furthermore the inter-
vention evoked mechanical and thermal hyperalgesia [38].
Nevertheless the activation of TS could be formed by
different CFA treatments, which results pain associated
pathological states, including migraine, neuralgias and
TMJ disorders [25]. In our previous study, we investi-
gated the effect of CFA on the expression of mitogen-ac-
tivated protein kinases (MAPK), which play essential
roles in pain processing. Administration of CFA in the
TMJ caused significant extracellular signal-regulated kin-
ase 1/2 (ERK1/2) and p38 MAPK increase in the TRG
[42]. Dural administration of CFA resulted elevated
ERK1/2, interleukin-1β and CGRP expression in the TRG
[11], as well as increased c-fos and glutamate immunore-
activity in the TNC and cervical neurons [43]. Moreover,
gene expression alterations (CGRP, Iba1, GFAP, etc.) were
detected following orofacial CFA treatment in the TRG
and TNC [12], which suggest that the CFA induced
neuroinflammation can evoke increased CGRP and
PACAP1–38 levels.
Role of neuropeptides in clinical studies
In migraineurs, the level of CGRP in the peripheral blood
increases during a migraine attack as compared to the
attack free [8, 39, 44, 45]. A very similar observation has
recently been made for PACAP1–38 as well, suggesting a
potential biomarker function of PACAP1–38 in the disease
[8]. In addition, similarly to CGRP [35], intravenous admin-
istration of PACAP1–38 induced headache and vasodilata-
tion, both in healthy subjects and patients suffering from
migraine, whereas it delayed migraine-like attacks only in
migraineurs [46, 47]. Magnetic resonance imaging angiog-
raphy examinations proved that PACAP1–38 induced
headache is associated with prolonged vasodilatation of the
middle meningeal artery (MMA), but not the middle cere-
bral artery (MCA). Sumatriptan was able to alleviate the
headache, which mirrored the contraction of the MMA,
but not the MCA, suggesting that PACAP1–38-induced
headaches may arise from the extracerebral arteries [48].
Correlation was showed between the interictal plasma
PACAP1–38 immunoreactivity and the microstructural
integrity of the white matter in migraineurs [5]. These data
support the idea that neuropeptides could be a good candi-
date for the new therapeutic approaches.
Nowadays the therapies based on monoclonal anti-
bodies of CGRP seem to be promising in the prevention
of migraine [49]. Recently, a phase 3 clinical trial showed
that 12 months of treatment with galcanezumab, which
is a fully humanized CGRP monoclonal antibody, was
safe and associated with a reduction in the number of
monthly migraine headache days [50]. Besides galcane-
zumab, erenumab, eptinezumab and fremanezumab
were able to reduce the frequency of attacks in patients
with episodic migraine [51].
Considering the similar behaviours of CGRP and
PACAP1–38, the therapies aimed at PACAP1–38 may
also be useful for those who have an inadequate response
to therapeutics directed at CGRP or its receptors. A phase
2a, randomized, double blind, placebo-controlled study is
underway to appraise the efficacy and safety of a PAC1
receptor antibody (AMG 301) in subjects with chronic or
episodic migraine (Study to Evaluate the Efficacy and
Safety of AMG 301 in Migraine Prevention. https://clini-
caltrials.gov/ct2/show/NCT03238781. Accessed 02 May
2018). Preclinical studies are also evaluating a monoclonal
antibody (ALD1910) targeting PACAP1–38 (ALD1910 –
migraine prevention. alderbio.com. https://www.alderbio.
com/pipeline/ald1910/. Accessed 19 May 2018, [10].
Monoclonal antibodies may be crucial in the therapy of
migraine however it needs further examinations to certify
their relevance.
Conclusion
Our results provided the first direct evidence that the ex-
pression levels of CGRP and preproPACAP simultaneously
increase after CFA induced trigeminal activation in the cen-
tral region of the TS. Correlations, which were found
between the alterations of CGRP/preproPACAP expression
and mechanical threshold prove the influence of neuropep-
tides in the mechanism of hyperalgesia. Data of the present
study contribute to the better understanding of migraine
pathogenesis and support the idea that neuropeptides may
have therapeutic value in migraine treatment.
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